Arming the immune system to fight cancer

January 8, 2014 by Faye Levine, University of Maryland

In 2004, a form of cancer known as neuroblastoma claimed the life of Alexandra (Alex) Scott, a little girl who gained national attention for using her lemonade stand to raise money for cancer research. Now, the organization established in her memory, the Alex's Lemonade Stand Foundation (ALSF), has awarded the University of Maryland's Christopher M. Jewell, an assistant professor in the A. James Clark School of Engineering, a three-year, $375,000 research grant to support the pre-clinical development of a cancer vaccine technology that could give children like Alex a better chance to have a long and healthy life.

Neuroblastoma, the third most common pediatric cancer, causes to turn into tumors. The prototype vaccine uses a unique combination of nanotechnology and immunology to "raise an army" of tumor-hunting immune cells, equip them to attack neuroblastoma, and leave them ready to reactivate if the cancer returns.

The lymph nodes are the body's immune system "command centers," packed with different types of immune cells. Each cell is equipped with a protein that responds to a particular disease or infection. Fragments of viruses, bacteria, and tumors collected in the lymph nodes are presented to these cells as antigens, molecules that provoke a response to a specific threat. When an immune cell encounters an antigen that it is designed to respond to, the cell "activates" and multiplies. These cells are then released into the blood and tissue to hunt their specific pathogens.

One type of activated immune cell, the central memory T cell, is particularly effective at infiltrating tumors. These cells start life as ordinary, inactive T cells in the lymph nodes that have the potential to become one of a number of active T cell types. Jewell's goal is to enhance the immune system's natural response by encouraging T cells to multiply and become central memory T cells specific for tumor antigens.

Jewell, a member of UMD's Fischell Department of Bioengineering, is an expert in immunomodulation, an emerging field that explores directing the body's response to target a specific disease. He believes crafting a biomaterials-based vaccine that not only provides T cells with the weapons to fight neuroblastoma, but also instructions on how, will give oncologists a new, more specific treatment option that relies more on the patient's own defenses than radiation and chemotherapy.

Creating any successful vaccine is difficult. Once injected, its components are dispersed around the body. Just a fraction of the vaccine reaches the lymph nodes, and its components are often so damaged or degraded by the trip they're no longer functional. Engineered microparticle and nanoparticle vaccines face additional challenges, because they are either too large to drain into lymph nodes or become too large because they stick to cells, proteins, or other particles.

Jewell's research group is developing a unique system in which controlled-release, biodegradable polymer "depots" are injected directly into the . The depots protect the vaccine components inside, control when they are released, and direct what happens next.

The vaccine contains two elements: the antigen that stimulates the T cells to attack , and "immune signals," small molecules that mimic the chemical signals use to communicate. The message, like the antigen, is another call to action: transform into central memory T cells, and multiply. Jewell hopes this approach will result in an army of central memory T cells prepared to destroy neuroblastoma tumors and capable of "remembering the enemy" later.

The cells' mission continues after the existing tumors are cleared. "Establishing these large populations of immunological memory cells could also help keep patients in remission by rapidly destroying tumor that might arise during relapse events," Jewell explains.

He adds that while the work is in the early stages, this technology could lead to new therapeutic technologies for treating other types of cancer.

"High risk tumors like neuroblastoma are treated with multiple therapeutic strategies with poor outcomes," says Dr. Anthony Sandler, chief of surgery at Children's National Medical Center, who is collaborating with Jewell on the project. "Cancer vaccines add another therapeutic option, but so far have had very limited success. The novel approach proposed in this work may provide the spark that stimulates effective immunity against the tumor."

"Cancer vaccines represent a new class of therapies, and biomaterials have great potential to treat cancers like neuroblastoma," says Jewell. "The ALSF's support and the clinical training we will receive through our collaboration with Children's National Medical Center have created an amazing opportunity. This investment will have a lasting impact on my lab's ability to contribute to the pediatric cancer field."

Explore further: Immune profile of lymph nodes nearest to tumor may predict melanoma progression

Related Stories

Immune profile of lymph nodes nearest to tumor may predict melanoma progression

January 6, 2014
(Medical Xpress)—Melanoma patients who had a specific subtype of immune cells called CD30-positive T cells in the lymph nodes closest to their tumors were more likely to have their disease progress within five years, according ...

Redirecting our immune cells to help fight children's cancer

November 6, 2013
Immune cells, known as Natural Killer T cells, could be redirected to help fight the childhood cancer, neuroblastoma, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool ...

Dendritic cell vaccine for relapsed neuroblastoma patient induces complete remission

January 29, 2013
One year after his last treatment, a six-year-old boy with recurrent neuroblastoma is in complete remission for his high-risk metastatic cancer. Doctors reported this case study in the January 2013 issue of Pediatrics, the ...

Researchers target cancer stem cells in malignant brain tumors

January 6, 2014
Researchers at the Cedars-Sinai Maxine Dunitz Neurosurgical Institute and Department of Neurosurgery identified immune system targets on cancer stem cells – cells from which malignant brain tumors are believed to originate ...

Researchers discover how cancer 'invisibility cloak' works

October 28, 2013
Researchers at National Jewish Health have discovered how a lipid secreted by cancer tumors prevents the immune system from mounting an immune response against it. When lysophosphatidic acid (LPA) binds to killer T cells, ...

Mexican research proposes alternative therapy against lung cancer

January 7, 2014
Research from the National Institute of Respiratory Diseases (INER) reveals that besides smoking, there are other factors associated with the development of lung cancer such as the smoke from burning lumber and coal, as well ...

Recommended for you

Single blood test screens for eight cancer types

January 18, 2018
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

Researchers find a way to 'starve' cancer

January 18, 2018
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital ...

These foods may up your odds for colon cancer

January 18, 2018
(HealthDay)—Chowing down on red meat, white bread and sugar-laden drinks might increase your long-term risk of colon cancer, a new study suggests.

The pill lowers ovarian cancer risk, even for smokers

January 18, 2018
(HealthDay)—It's known that use of the birth control pill is tied to lower odds for ovarian cancer, but new research shows the benefit extends to smokers or women who are obese.

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.